Company Encyclopedia
View More
name
HANSOH PHARMA
03692.HK
Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People’s Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Zefei, Xintai, Xinmei, Gainuo, Tanneng, and Pulaitan; Hengmu, Mailingda, Hengsen, Oulanning, Ailanning, and Ameining; XINYUE; and Saint Luolai, Fulaimei, Ruibote, Fulaidi, Fulairui, Punuoan tablets, etc. It has licence agreements with GlaxoSmithKline Intellectual Property (No.4) Limited to develop, manufacture, and commercialize HS-20089 and HS-20093 for the treatment of patients with extensive-stage small-cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy; Biotheus Inc.
1.450 T
03692.HKMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
B
PharmaceuticalsIndustry
Industry Ranking2/48
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE16.21%A
    • Profit Margin36.25%A
    • Gross Margin90.89%A
  • Growth ScoreB
    • Revenue YoY9.18%B
    • Net Profit YoY1.58%C
    • Total Assets YoY12.79%B
    • Net Assets YoY13.52%B
  • Cash ScoreC
    • Cash Flow Margin275.85%C
    • OCF YoY9.18%B
  • Operating ScoreC
    • Turnover0.4C
  • Debt ScoreA
    • Gearing Ratio11.33%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    The Hang Seng Index closed at 26,085 points, up 149 points; the Hang Seng Tech Index closed at 5,662 points, up 47 points. Ping An rose over 6%, HANSOH PHARMA, ENN ENERGY, and Sinotruk hit new highs with active trading

    The Hang Seng Index closed at 26,085 points, up 149 points; the Hang Seng Tech Index reported 5,662 points, up 47 points. Ping An rose by 6.7%, HANSOH PHARMA, ENN ENERGY, and Sinotruk hit new highs. The total market turnover was HKD 210.473 billion

    AASTOCKS·
    US
    XNGSY
    +2.66%
    HK
    02688
    +1.51%
    HK
    03692
    +3.66%
    AASTOCKS·
    US
    XNGSY
    +2.66%
    HK
    02688
    +1.51%
    HK
    03692
    +3.66%

    According to the "All-Day Express," the Hang Seng Index closed at 25,945 points, up 17 points; the Hang Seng Tech Index closed at 5,598 points, down 20 points. POP MART rose over 6%, HANSOH PHARMA, MTR CORPORATION, LEE & MAN PAPER, GLOBAL NEW MAT, and ND PAPER reached new highs with active trading

    The Hang Seng Index closed at 25,945 points, up 17 points; the Hang Seng Tech Index reported 5,598 points, down 20 points. POP MART rose 6.8%, HANSOH PHARMA, MTR CORPORATION, LEE & MAN PAPER, GLOBAL NEW MAT, and ND PAPER reached new highs. Alibaba fell 2.7%, Xiaomi rose 2.5%, and Tencent fell 1.3%. The total market turnover was HKD 204.728 billion

    AASTOCKS·
    HK
    09992
    +1.67%
    HK
    00066
    -0.83%
    HK
    02689
    -0.47%
    AASTOCKS·
    HK
    09992
    +1.67%
    HK
    00066
    -0.83%
    HK
    02689
    -0.47%

    According to the Hong Kong Daily News, the Hang Seng Index rose by 496 points; the Hang Seng Tech Index increased by 150 points. Alibaba rose by over 4%, HANSOH PHARMA and Evergrande Property reached new highs, with active trading

    The Hang Seng Index rose 496 points to 25,716 points, an increase of 2.0%. The Hang Seng Tech Index rose 150 points to 5,545 points, an increase of 2.8%. Alibaba rose 4.7%, and HANSOH PHARMA reached a new high. The total market turnover reached HKD 302.642 billion

    AASTOCKS·
    HK
    03692
    +3.66%
    US
    BABA
    -0.40%
    HK
    09988
    +0.39%
    AASTOCKS·
    HK
    03692
    +3.66%
    US
    BABA
    -0.40%
    HK
    09988
    +0.39%

    Hong Kong Shares Rebound to Kick Off the Week

    Hong Kong stocks rebounded on Monday, climbing 1.0% to 25,478, ending a six-session losing streak. Gains were driven by bargain hunting in property, financials, and tech shares, and a rise in U.S. futures. Support also came from Premier Li Qiang's remarks on China's mineral curbs. Gains were limited by caution ahead of upcoming economic data. Top performers included Innovent Biologics, Hansoh Pharma, and Akeso Inc.

    Trading Economics·
    HK
    09926
    +0.57%
    HK
    01801
    -1.66%
    HK
    03692
    +3.66%
    Trading Economics·
    HK
    09926
    +0.57%
    HK
    01801
    -1.66%
    HK
    03692
    +3.66%

    Hansoh Pharmaceutical Group Company Limited (3692) Receives a Buy from UBS

    UBS analyst Anita Wei has maintained a Buy rating on Hansoh Pharmaceutical Group Company Limited (3692) as of November 11, with a price target of HK$48.20. The stock closed at HK$36.50. The overall analyst consensus for Hansoh is a Strong Buy, with an average price target of HK$43.91.

    Tip Ranks·
    HK
    03692
    +3.66%
    Tip Ranks·
    HK
    03692
    +3.66%
    © 2025 Longbridge｜Disclaimer